Developing therapies for human diseases continues to face obstacles, particularly in translating targets or compounds identified by in vitro screening campaigns to valid targets or efficacious and safe compounds once tested in humans. Here we discuss strategies that leverage induced pluripotent stem cells (iPSCs) to increase the relevance of cell models for these in vitro approaches. We review current advances in genome engineering and how to leverage a portfolio of these tools to generate knock-out and knock-in models for use in target or compound identification. Specifically, we demonstrate this approach with induced pluripotent stem cells (iPSCs) to build isogenic disease models, which can be further differentiated to various cell types of interest that are more directly related to a disease area than commonly used immortalized cell lines. We expect strategies combining genome engineering and stem cells to provide platforms for more robust disease models that will provide more predictable translation of in vitro to in vivo results.
Molecular Biology
Biotechnology
Cell Biology
Cell Culture
Neuroscience
Genetics
Cancer Research
Gene Expression
Clinical Research
Dna
Immunology
Crispr-Cas9
Pcr/rt-Pcr/real-Time Pcr
Biomarkers
Gene Editing
Europe47%
North America25%
Asia22%
South America3%
Oceania1%
Africa1%
Website Visitors100%
Research Scientist19%
Student14%
Post Doc14%
Educator/Faculty10%
Medical Doctor/Specialist8%
Executive8%
Scientist6%
Facility/Department Manager5%
Biologist5%
Engineer3%
Lab Management2%
Marketing/Sales2%
Veterinarian2%
Clinical Laboratory Scientist2%
Animal Care Lab Technician2%
Academic Institution23%
Research Institute6%
Pharmaceutical Company5%
Veterinary School4%
Medical Center4%
Hospital4%
Biotech Company4%
Medical School3%
Contract Research Organization (Cro)3%
Life Science Company3%
Government3%
Government/public1%
Medical Device Company1%
Distribution/sales1%
Other5%